Success Metrics

Clinical Success Rate
69.2%

Based on 9 completed trials

Completion Rate
69%(9/13)
Active Trials
2(9%)
Results Posted
22%(2 trials)
Terminated
4(18%)

Phase Distribution

Ph early_phase_1
1
5%
Ph not_applicable
15
68%
Ph phase_1
4
18%
Ph phase_2
2
9%

Phase Distribution

5

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution22 total trials
Early Phase 1First-in-human
1(4.5%)
Phase 1Safety & dosage
4(18.2%)
Phase 2Efficacy & side effects
2(9.1%)
N/ANon-phased studies
15(68.2%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

56.3%

9 of 16 finished

Non-Completion Rate

43.8%

7 ended early

Currently Active

2

trials recruiting

Total Trials

22

all time

Status Distribution
Active(2)
Completed(9)
Terminated(7)
Other(4)

Detailed Status

Completed9
unknown4
Terminated4
Withdrawn3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
22
Active
2
Success Rate
69.2%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (4.5%)
Phase 14 (18.2%)
Phase 22 (9.1%)
N/A15 (68.2%)

Trials by Status

completed941%
unknown418%
terminated418%
withdrawn314%
active_not_recruiting29%

Recent Activity

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT01653093Not Applicable

3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer

Active Not Recruiting
NCT05391906Not Applicable

Intravoxel Incoherent Motion (IVIM) Magnetic Resonance Imaging in Multiple Sclerosis

Active Not Recruiting
NCT01564368Not Applicable

DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy

Completed
NCT00474604Not Applicable

Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants

Completed
NCT05786170Not Applicable

ERILs Und SNILs Unter SOC

Withdrawn
NCT01967862Not Applicable

Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer

Completed
NCT02277561Not Applicable

Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery

Withdrawn
NCT01739439Phase 1

Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery

Terminated
NCT02269111Not Applicable

Quantitative MRI in Assessing Disease in Patients With Brain Tumors

Terminated
NCT01390571Phase 1

Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma

Completed
NCT01825902Early Phase 1

18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma

Completed
NCT01263821Not Applicable

Image Guided Therapy in the Treatment of Gliomas

Terminated
NCT02059889Not Applicable

Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer

Withdrawn
NCT01938651Not Applicable

Ultra High Field MRI and MRS Techniques in Diagnosing Breast Cancer

Terminated
NCT02237612Not Applicable

Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer

Completed
NCT00967954Not Applicable

Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer

Unknown
NCT00100880Phase 1

Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors

Completed
NCT01193855Phase 2

Dutasteride in Treating Patients With Prostate Cancer

Unknown
NCT01124682Phase 1

3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder

Unknown
NCT00978770Phase 2

MRI in Predicting Early Response to Chemotherapy in Patients With Locally Advanced Breast Cancer

Completed

Drug Details

Intervention Type
PROCEDURE
Total Trials
22